Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-6432

PURPOSE: The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism. This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to inform dosing recommendations in these special populatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: LoRusso, Patricia M, Venkatakrishnan, Karthik, Ramanathan, Ramesh K, Sarantopoulos, John, Mulkerin, Daniel, Shibata, Stephen I, Hamilton, Anne, Dowlati, Afshin, Mani, Sridhar, Rudek, Michelle A, Takimoto, Chris H, Neuwirth, Rachel, Esseltine, Dixie-Lee, Ivy, Percy
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3834726/
https://ncbi.nlm.nih.gov/pubmed/22394984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2873
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados